



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/566,094	10/03/2006	Ramon Merce Vidal	284057US0PCT	9552
22850	7590	07/24/2009		
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314				
EXAMINER				
RICCI, CRAIG D				
ART UNIT		PAPER NUMBER		
1614				
NOTIFICATION DATE		DELIVERY MODE		
07/24/2009		ELECTRONIC		

**Please find below and/or attached an Office communication concerning this application or proceeding.**


The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com  
oblonpat@oblon.com  
jgardner@oblon.com

**11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:**

1. As discussed in the previous Action mailed on 02/23/200+, the instant invention is drawn to compounds which are useful as 5-HT<sub>6</sub> modulators. Specifically, instant claim 1 is drawn to compounds of formula (Ia) which encompasses the following specific compound




wherein R<sup>1</sup> is NR<sup>8</sup>R<sup>9</sup> and R<sup>8</sup>R<sup>9</sup> together



with the bridging nitrogen atom form a saturated heterocyclic ring, specifically ;  
R<sup>2</sup>-R<sup>7</sup> are hydrogen; and A is a polycyclic aromatic ring system, wherein the rings are 6 membered. Specifically, the above compound is disclosed in the instant Specification as N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-naphthalene-1-sulfonamide (Page 78, Example 17) and the compound reads on claims 1-8 and 76-82.

2. *Merce-Vidal et al* teach compounds which are useful as 5-HT<sub>6</sub> modulators. In particular, *Merce-Vidal et al* disclose the compound N-{3-[2-(pyrrolidin-1-yl)-ethyl]-1H-indole-5-yl}-naphthalene-1-sulfonamide, having the following structure:



(Page 6, Example 45). Accordingly, the only difference between the instant species and that taught by *Merce-Vidal et al* is the placement of -(CH<sub>2</sub>)<sub>n</sub>-R<sub>1</sub> (wherein -(CH<sub>2</sub>)<sub>n</sub>-R<sub>1</sub> in the instant invention and in *Merce-Vidal et al* are the same) on the indole core. As discussed in the previous Action, the compounds are thus positional isomers of each other, and the subtle difference between the compound taught by *Merce-Vidal et al* and the instantly claimed species is *prima facie* obvious in view of *In re Wilder*, 563 F.2d 457 (CCPA 1977).

3. Applicants, however, traverse this finding on the grounds that *In re Wilder* notes that such positional isomers are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties and, in the instant case, "even if it were the case that the claimed compounds are simply position isomers or homologs of the compounds disclosed by *Merce-Vidal et al*, Applicants... have provided bibliographic evidences... to provide that the different biological properties between 1-substituted and 3-substituted indoles are known from the prior art" (Applicant Argument, Page 7). Indeed, as

noted by the court in *Takeda Chemical Industries, LTD. V. Alphapharm PTY., LTD.*, 492 F.3d 1350, citing *In re Deuel*, 51 F.3d 1552 (Fed. Cir. 1995), “[n]ormally a *prima facie* case of obviousness is based upon structural similarity, i.e., an established structural relationship between a prior art compound and the claimed compound.’ That is so because close or established ‘[s]tructural relationships may provide the requisite motivation or suggestion to modify known compounds to obtain new compounds.’ A known compound may suggest its homolog, analog, or isomer because such compounds ‘often have similar properties and therefore chemists of ordinary skill would ordinarily contemplate making them to try to obtain compounds with improved properties.’” (at page 1356). However, the court (quoting *In re Grabiak*, 769 F.2d 729 (Fed. Cir. 1985) also noted that “since our *Wilder* decision, we have cautioned ‘that generalization should be avoided insofar as specific chemical structures are alleged to be *prima facie* obvious from one another’” (at page 1361) and that “in order to find a *prima facie* case of unpatentability in such instances, a showing that the ‘prior art would have suggested making the specific molecular modifications necessary to achieve the claimed invention’ was also required.” (at page 1356). Thus, in *Takeda*, the court found no motivation existed in the prior art for one of ordinary skill in the art to modify a prior art compound by homologation and ring-walking to arrive at the claimed compound and wherein the claimed compound further exhibited unexpectedly superior properties over the prior art compound.

4. Despite Applicants assertions, the instant case is distinguishable from *Takeda* in that the prior art compound taught by *Merce-Vidal et al* differs from the instantly claimed compound in only one respect (i.e., ring walking the moiety from position 3 to position 1) whereas in *Takeda*, the compounds differed in two respects. Furthermore, nowhere have Applicants provided

evidence to suggest that the one difference in the instant case, i.e., the ring walking, was not a routine step in the drug optimization process at the time the instant invention was made (as was the case in *Takeda*; see page 1360). Also, unlike in *Takeda*, the specific molecular modifications necessary to achieve the claimed invention are motivated in further view of *Filla et al.* As previously discussed, *Filla et al* teach compounds which (like *Merce-Vidal et al*) are 5-HT<sub>6</sub> modulators possessing an indole core. However, the compounds of *Filla et al* are substituted at position 1 of the indole core. Accordingly, the skilled artisan - who would ordinarily contemplate making isomers of the compound taught by *Merce-Vidal et al* to try to obtain compounds with improved properties - would consider ring-walking the moiety to position 1 of the indole core with the reasonable expectation that compounds possessing such modification would still function as 5-HT<sub>6</sub> modulators and possibly possess improved properties. Finally, there is nothing in the record to indicate that the instantly claimed compound possesses any unexpectedly superior properties over the prior art compound taught by *Merce-Vidal et al* such as, for example, reduced toxicity (as in *Takeda*) to overcome this *prima facie* rejection.

5. Applicants point to indole-containing compounds which are positional isomers of each other but which have distinct activities (Applicant Argument, Pages 8-9). However, Applicants' argument remains unpersuasive since, as previously noted, none of the compounds referenced are drawn to modulators of 5-HT<sub>6</sub>. Furthermore, although it is clear that the referenced compounds are known to have different activities, it is not clear that the compounds also *lack* the same activity. That is, whereas compound (1) is claimed as an inhibitor of thromboxane A<sub>2</sub> synthesis in WO 9320065 while its positional isomer compound (2) is described as a selective h5-HT<sub>1D</sub> receptor agonist, there is no evidence that compound (1) was assayed to evaluate its

activity as a selective h5-HT<sub>1D</sub> receptor agonist and was determined to not possess such activity, and *vice versa*. The same reasoning applies to the compounds relied on by Applicants at Pages 9-10; namely, there is nothing to suggest that the RN 137642-51-4 does not possess 5-HT<sub>6</sub> activity even though it is not indicated as such. Moreover, *assuming arguendo* that RN 137642-51-4 does not possess such 5-HT<sub>6</sub> activity, since the compounds differ in three respects (two ring walking modifications and one halogen substitution) it would be impossible to ascertain whether the difference in activity was due to a single ring-walking modification as in the instant case. Additionally, the fact that the instant compound does not possess a tryptamine-like structure is not considered persuasive. Example 28 in *Filla et al* (Page 67) does not appear to possess a tryptamine-like structure any more than the instantly claimed compound possesses said structure, yet Example 28 is disclosed as a 5-HT<sub>6</sub> modulator. Thus, it is not found persuasive that the skilled artisan would have expected maintaining the tryptamine-like structure in the compounds taught by *Merce-Vidal et al* to be critical for their activity as 5-HT<sub>6</sub> modulators.


6. Thus, since Applicants have not provided evidence to demonstrate that ring walking was not a routine step in the drug optimization process at the time the instant invention was made and since Applicants have also not introduced sufficient evidence to overcome the presumption that positional isomers are generally of sufficiently close structural similarity that such compounds possess similar properties, the arguments are not found persuasive.

7. Applicants further argue that *Filla et al* (which discloses 5-HT<sub>6</sub> receptor modulators possessing an indole core which is substituted at position 1) does not contain the exact substituent at position 1 as is disclosed by the prior art compound taught by *Merce-Vidal et al* (wherein the substituent is located at position 3) and recited by the instant claims. Nevertheless,

*Filla et al* indicates that substitution of the indole core at position 1 does not disrupt the compound's activity as a 5-HT<sub>6</sub> modulator. The fact that the compounds taught by *Filla et al* do not contain the exact substituent at position 1 as is taught in the instant claims would not dissuade the person of ordinary skill in the art from making the compounds since the skilled artisan would seek to ring-walk to the substituent taught by *Merce-Vidal et al* to a position (such as position 1 as taught by *Filla et al*) capable of supporting a similar substituent and maintaining activity as a 5-HT<sub>6</sub> modulator. As such, as discussed above, the skilled artisan - who would ordinarily contemplate making isomers of the compound taught by *Merce-Vidal et al* to try to obtain compounds with improved properties - would consider ring-walking the moiety to position 1 of the indole core with the reasonable expectation that compounds possessing such modification would still function as 5-HT<sub>6</sub> modulators and possibly possess improved properties.

8. Accordingly, for all of the foregoing reasons, Applicants' arguments are not found persuasive. The rejection of claims 18-19, 46-47, 74-75, 84-85 and 92-93 in the previous Action and which are not specifically traversed beyond the traversals discussed above is maintained.

9. The rejection of claims 9 and 86-90 based on N-[3-(2-dimethylaminoethyl)-1H-indole-5-yl]-naphthalene-1-sulfonamide (Page 5, Line 3, Example 8) having the following structure:



in the previous Action is also maintained for the same reasons as discussed above.

/Ardin Marschel/

Supervisory Patent Examiner, Art Unit 1614